Redona Therapeutics

Redona Therapeutics

  • Founded: 2016
  • Location: Watertown, MA
  • Employee range: 11 - 50
  • Clinical stage: RD
  • Therapy area: oncology, autoimmune diseases, telomere diseases/HPV
  • Drug types: ONC, IMM, INF
  • Lead product: various
  • Product link:
  • Funding: $15M A May 2019; $65M A Sep 2018
  • Investors: Sofinnova Partners, Osage University Partners, MPM Capital, Novartis Venture Fund, Johnson & Johnson Innovation, Vertex Ventures HC, Longwood Fund, Astellas Venture Management

job board

Short description:

Small Molecules to Target ncRNA Biology

Drug notes:

Contact us to add description:

Long description:

Redona Therapeutics is developing small molecule therapies to target nucleic acid regulators. Processing and sensing of nucleic acids can become dysregulated, developing into serious diseases like cancer and autoimmune disease. This method of targeting enzymes that regulate RNA or DNA can effect several disease hallmarks rather than just a single pathway. These regulators may be involved in critical cellular processes like DNA or RNA stability, sensing, replication, repair, or RNA splicing. Redona aims to restore these dysregulated processes in severe disease, producing a therapeutic benefit to patients. Redona also hopes to partner with others in order to determine other applications of their technologies outside of cancer and autoimmune disease.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy